Drug intelligence / Profile preview

MI-10-022

Development stage: Unknown
Lead developer: Mithridion
Modality: Small Molecules

Overview

**MI-10-022** is a small molecule dual agonist targeting muscarinic acetylcholine receptors M1 and M4. These receptors are implicated in cognitive function and psychiatric disorders, with M1 activation enhancing memory and attention, and M4 modulation influencing dopamine signaling relevant to schizophrenia. Initially developed by Mithridion, Inc., a company focused on neurological therapies, the compound aimed to address unmet needs in cognitive impairment associated with neuropsychiatric conditions like Alzheimer's disease and schizophrenia through selective cholinergic potentiation.

Targets

CHRM4 (M4)M1 (Muscarinic acetylcholine receptor M1)

Beyond the preview

Go deeper on MI-10-022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MI-10-022.

Explore the full profile